EarliPoint provides an objective, validated, predictive biomarker for ASD with the potential to reduce the time between the first signs of autism and intervention.

#TheDefender

https://childrenshealthdefense.org/defender/eye-test-earlipoint-autism/?utm_source=sovren&utm_medium=social&utm_campaign=defender&utm_id=20230913

Deborah Byrd - Life’s building blocks found in Orion Nebula:

https://earthsky.org/space/lifes-building-blocks-found-in-orion-nebula/

#OrionNebula #OrionBar #Biomarker #Carbon #MethylCation #CH3Plus #D203506 #RedDwarf #JamesWebb #SpaceTelescope #JWST #NASA #OrganicChemistry #Chemistry #Astronomy

Analysis of Exosome Therapeutics market Strategies and Forecasts to 2035

The “Exosome Therapeutics Market, 2022-2040” report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the exosome therapies in the treatment of various diseases.

Key Inclusions
 General introduction to exosomes, types of extracellular vesicles and their origin, secretion, and type of membrane. In addition, it provides information on the development process of exosomes and details on applications of exosomes, mechanism of different therapies, along with the advantages, risks associated with exosome therapeutics and the future perspectives.
 A detailed assessment of the current market landscape of exosome therapeutics, based on several relevant parameters, such as phase of development (clinical and preclinical), technology platform (DeliverEXTM platform, iPSC Platform, engEx™ Platform, mTEV Platform, PEP Exosome Technology and others), type of payload (protein, biologics, RNA, vaccine, antisense oligonucleotide, DNA / protein and AAV capsids), target disease indication (s) (COVID-19, acute respiratory distress syndrome, skin regeneration, cancer and others), therapeutic area (oncological disorders, dermatological disorders, neurological disorders, infectious diseases, rare disorders, autoimmune disorders and respiratory disorders and others), biological target, route of administration (intravenous, oral, subcutaneous, intratumoral, nasal and others), type of therapy (monotherapy and combination therapy), combination drug, line of treatment and dosing frequency. In addition, it provides details on the companies engaged in the development of exosome therapeutics, along with information on their year of establishment, company size and location of headquarters.
 Elaborate profiles of the key players engaged in the development of exosome therapeutics, with maximum number of therapeutic programs in their pipeline. Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio and a section on recent developments and an informed future outlook.
 Elaborate drug profiles of the key therapeutics . Each profile features a brief information on product portfolio and clinical trial information including study title, study detail, status of trial, phase of development, trial location, patient enrollment, study start and end date.
 A detailed analysis of completed and ongoing clinical trials of various exosome therapeutics, based on different parameters, such as trial status, trial registration year, type of sponsor / collaborator, study design, and number of patients enrolled. In addition, the chapter highlights year-wise trend of completed and recruiting trials, age group of the patients enrolled, active industry and non-industry players and location of the trials.
 An in-depth analysis of academic grants that have been awarded to various research institutes for projects related to exosome therapeutics, during the period, 2017-2022, based on several parameters, such as year of grant awarded, amount awarded, type of funding institute center, popular NIH departments, support period, emerging focus area, purpose of grants, grant activity code, local recipients, type of recipient organization study section and type of grant application. Further, the chapter also highlights the popular recipient organizations, (in terms of number of grants and amount awarded).
 A detailed analysis of the global events attended by the exosome therapy developers, based on several relevant parameters, such as year of event, type of event platform, location of event, emerging focus areas, active organizers (in terms of number of events), active industry and non-industry participants, designation of participants, affiliated department of participants, and active speakers (in terms of number of events).
 An analysis of the partnerships that have been established in this domain since 2017, covering instances of research agreement, licensing agreement, manufacturing agreement, product development and commercialization agreement, merger / acquisition, and other relevant deals.
 A detailed analysis of the various investments made since 2017, including grant / award, seed financing, venture capital financing, IPOs, secondary offering, debt financing, other equity, in companies focused on the development of exosome therapeutics.
 An analysis of start-ups / small companies engaged in the development of exosome therapeutics, based on parameters, such as pipeline strength, pipeline maturity, financial support, number of investors, partnership activity and start-up health indexing.
 A case study highlighting the companies engaged in offering exosome development and manufacturing services along with the information on their year of establishment, company size, location of headquarters, types of service(s) offered (isolation, characterization, purification, chromatography, engineering, targeted delivery, diagnostic biomarker, and quality control), method of isolation, method of purification, method of characterization, method of exosome manufacturing (engineering and targeted delivery), scale of operation (discovery / research, pre-clinical, clinical or commercialized) and scalability (small, mid-sized or large).
 An in-depth analysis of exosome therapeutics that failed to progress to later stages of clinical development, based on various relevant parameters, such as trial status of discontinuation, target disease indication(s), route of administration and type of sponsor.

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

 Type of Therapeutic
 Allogeneic Therapy
 AutologousTherapy

 Target Indication(s)
 Degenerative Meniscal Injury
 Dystrophic Epidermolysis Bullosa
 Fistula Perianal
 Retinitis Pigmentosa

 Therapeutic Area
 Dermatological Disorders
 Muscoskeletal Disorders
 Ophthalmic Diseases
 Rectal Disorders


 Route of Administration
 Fistula Tract
 Intra-articular
 Intra-ocular

 Geography
 North America
 Europe
 Asia-Pacific and Rest of the World

Key Questions Answered
 Who are the leading industry and non-industry players engaged in the development of exosome therapies?
 Which are the key drugs being developed across early and late stages of development?
 What are the key agendas being discussed in various global events / conferences related to exosomes?
 What kind of partnership models are commonly adopted by industry stakeholders?
 Which are the leading funding institutes / centers supporting the research related to exosome therapies?
 Which geographies are the most active in conducting clinical trials related to exosome therapies?
 How is the current and future market opportunity, related to exosome therapies likely to be distributed across key market segments?

To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/exosome-therapeutics-market.html

You may also be interested in the following titles:
mRNA Synthesis and Manufacturing Services Market

Lab Automation Market


You may also like to learn what our experts are sharing in Roots educational series:
Long-Acting Drug Delivery: A Novel Pharmacological Strategy to Deliver Therapeutic Modalities

Digital Therapies: The “Digital Pills” of current generation



About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com


#Exosome Therapeutics Market Trends #Exosome Therapeutics Market Growth #exosometherapies #exosometherapies